Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 22, 2015 4:20 PM ET

Biotechnology

Company Overview of Ambit Biosciences Corporation

Company Overview

Ambit Biosciences Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of oncology, autoimmune, and inflammatory diseases in the United States. The company’s products include quizartinib, an orally administered FMS-like tyrosine kinase 3 inhibitor that has completed Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia. Its drug candidates also comprise AC410, a small molecule inhibitor of Janus kinase 2, which is in Phase 1 clinical trials; and AC708, a receptor tyrosine kinase inhibitor that is in pre-clinical studies for the treatment of oncology, autoimmune, and i...

11080 Roselle Street

San Diego, CA 92121

United States

Founded in 2000

53 Employees

Phone:

858-334-2100

Fax:

858-334-2192

Key Executives for Ambit Biosciences Corporation

Chief Executive Officer and President
Age: 57
Founder
Age: 68
Co-Founder, Chairman of Scientific Advisory Board
General Counsel and Senior Vice President
Age: 48
Vice President
Compensation as of Fiscal Year 2014.

Ambit Biosciences Corporation Key Developments

Ambit Biosciences Corporation Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Ambit Biosciences Corporation Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015. Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States. Presentation Date & Speakers: Feb-25-2015, Alan Fuhrman, Chief Financial Officer and Principal Accounting Officer. Feb-26-2015, Michael A. Martino, Chief Executive Officer and President.

Ambit Biosciences Corporation Announces Executive Resignations

Ambit Biosciences Corporation announced resignation of David Bonita, Faheem Hasnain, Jeffrey S. Hatfield, Standish M. Fleming, Mark G. Foletta, Allan P. Marchington, Michael A. Martino, David Parkinson and Isai Peimer as a Board of Directors and any committees thereof, of Ambit.

Ambit Biosciences Corporation(NasdaqGM:AMBI) dropped from NASDAQ Composite Index

Ambit Biosciences Corporation will be removed from the NASDAQ Composite Index.

Similar Private Companies By Industry

Company Name Region
Genelux Corporation United States
EnGenCore LLC United States
Coeurative, Inc. United States
AgBiome, LLC United States
C5-6 Technologies Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 28, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ambit Biosciences Corporation, please visit www.ambitbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.